The Late-Breaking Research Abstract Program
2027 Abstract Submission Guidelines and Procedures

The American Academy of Dermatology is delighted to announce its 2027 Late-Breaking Research Program. Researchers are invited to submit abstracts describing their latest results. Authors from the top-scoring studies will be invited to present their findings at the 2027 Annual Meeting. Selected presentations will highlight the latest trailblazing research in dermatology. The Abstract Committee will consider all well-conducted, scientifically rigorous studies from basic science to clinical trials.

SUBMISSIONS

All submissions will be reviewed by a team of expert reviewers and the top abstracts selected will reflect the best research from all aspects of dermatological science. Industry researchers may NOT provide product recommendations during their presentations. **Abstract submissions are limited to 250 words** (the 250-word count applies to all text in the "abstract" textbox).

Abstracts should be organized with the following information:

- **Background**: Why is the disease/question important? How does your study address this problem?
- **Type of Study** (e.g., cross-sectional study, phase III trials, etc.)
- **Methods**
- **Results** (include p-values and statistical tests if appropriate). Abstracts will be judged only on results provided in the submission.
  *Abstracts citing promissory data (e.g. "final results will be presented at the meeting") will not be considered.
- **Conclusion**: How are your findings novel? How do (or will) your results impact the disease?
  *Images and tables will NOT be accepted during the submission process. Only text and numbers are allowed.

Priority will be given to:

- Groundbreaking first-in-human trials
- Phase II/III and head-to-head clinical trials
- Extensive population-based epidemiologic and genetic studies
- Innovative new transformative technologies
- Translationally relevant biomarker studies
- Basic science research that sheds light on mechanisms of disease, therapy, or adverse events.

Other Considerations:

- Systematic reviews and meta-analyses are generally discouraged unless there is novel insight that could potentially change practice.
- Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown.

Abstracts submitted will be reviewed and graded via a blinded review process. No identifiable information (e.g., investigator, institution names) is included in the review process. Abstracts should clearly identify the research background, approach, results, innovation, and relevance of their research to dermatology.

Abstracts must be submitted by **11:59 AM CT on January 20, 2027** via the AAD website. After this date/time, the submission site will close automatically, and we will no longer accept submissions. There will be **no exceptions** to this policy.

ELIGIBILITY REQUIREMENTS

- All members of the Academy are invited to submit abstracts for review and selection.
- Non-members and guests from outside the United States are welcome to submit abstracts provided they are submitted in English.
- The Academy encourages medical students, residents, and fellows to present new material at the Annual Meeting.
- If you submit the same abstract to multiple abstract programs and your abstract is accepted to more than one of the programs, you will be required to choose one program in which to present. The abstract will be withdrawn from the other program(s).
  - The author is responsible for contacting the AAD to confirm the program in which they will be participating via email to abstracts@aad.org.
- By submitting the abstract, the Primary Author or the backup speaker listed on the initial submission agree to present the abstract as an oral presentation at the Annual Meeting.

- DO NOT submit an abstract for consideration if you cannot ensure that a speaker will be at the meeting if your abstract is accepted. It is the responsibility of the primary author to inform the AAD if they cannot present and provide an alternate presenter if possible.
- Only a co-author, listed on the original submission, will be accepted as an alternate presenter. MAKE SURE ALL AUTHORS ARE INCLUDED IN THE ORIGINAL SUBMISSION, as you are unable to edit the submission after the deadline.
- The same author can be listed as the Primary Author on multiple abstracts. If more than one abstract is accepted, the Primary Author can only present one of the abstracts. A co-author, present at the AAD meeting, must be chosen as an alternate presenter on any concurrent accepted abstracts. An author can only present one accepted abstract within the Late-breaking Abstract session(s).

- There is a limit of **10 authors per submission plus the Primary Author** (11 total).
  - At least one author listed on the submission needs to be a **current AAD member**.
  - Authors should be entered in the order that they will be published, starting with the 'Primary Author'.
  - This information **cannot be changed** once the abstract is submitted.
- If your submission is accepted, you must register to attend the meeting and pay the appropriate registration.
- Applicants are required to disclose any financial relationships with commercial companies. If an author has no financial relationships, they must add a comment stating, 'Author has no relevant financial relationships to disclose.'

What is Not Eligible for Submission:

- Case reports and small case series (<5 cases) are inappropriate for this session
- Purely hypothesis generating clinical research such as analysis of case reports, pharmacovigilance reports (for example, analyses of FAERS), unless truly novel, or accompanied with hypothesis testing approaches (e.g., cohort, case-control, clinical trial, and/or mechanistic laboratory studies) are not appropriate for Late-Breaking Research abstracts. Clinical research using administrative claims or electronic medical record data (for example, TriNetX) should have evidence that the codes validly represent the variables being studied and that the data are complete enough to yield valid inferences or will not be considered for the Late-Breaking Research abstract program.
- An abstract is ineligible for consideration if it reports work that has been published or was accepted for publication as a manuscript that will be published prior to the scheduled presentation time at the Annual Meeting (e.g., full-length article, brief report, case report, concise communication or letter to the editor, in press articles).
  - Manuscripts under revision are eligible.
- bioRxiv/medRxiv posting is not permitted.
- Submitted abstracts must be the original work of the listed authors. **The use of generative artificial intelligence or AI-assisted tools is prohibited.** This does not restrict assistive technologies used for accessibility (screen readers, dictation software, etc.), provided the intellectual content is authored by the individuals listed.
- Applicants should not submit abstracts that include material already presented at previous Academy meetings or other scientific meetings within the United States or abroad.
- The same study should not be submitted as multiple abstracts. Abstracts that appear as more than one version of a single study will be withdrawn without notice.
- Submissions will be withdrawn without notice if they utilize any materials/slides that have been created by a commercial entity and include promotional messages and/or corporate logos. QR codes are acceptable in the final presentations as long as they do not link to any promotional messaging or logos.

DATA ANNOUNCEMENT AND PRESENTATIONS

It is expected that the first public announcement of these groundbreaking results will occur at the Late Breaking Abstract sessions during the 2027 AAD Annual Meeting.

- Accepted abstracts are strictly **confidential and embargoed** until the designated release time. All abstract content accepted for presentation in the Late-Breaking Research session(s) must not be released prior to the official embargo time listed below. Anyone determined by AAD to have violated the embargo policy may be withdrawn from the Late-Breaking Research abstract program.
  - **Late-Breaking Session 1:** content embargoed until 9:00 AM PT, Saturday, March 20, 2027
  - **Late-Breaking Session 2:** content embargoed until 1:00 PM PT, Saturday, March 20, 2027
  - At that time, the abstracts will be made available and posted online as a session handout. However, the title and authors of the abstracts will be listed in the online searchable program for audience interest leading up to the start of the meeting.

- The American Academy of Dermatology allows for exceptions to the embargo policy when federal and international laws require disclosure of specific clinical trial results; however, the press release should include only details necessary to comply with the regulation.
- Only high-level statements, without quantitative or interpretive language, may be released. Final adjudication is at the discretion of the AAD. If data, statistical analyses, and quantitative or interpretive statements regarding the implication for practice are released before the embargo date and time, the Academy retains the right to withdraw the abstract. The draft press release should be shared with the Academy as soon as possible to determine eligibility. Requests should be forwarded to abstracts@aad.org and will be reviewed on a case-by-case basis.

If accepted,

- The final session schedule will depend on the number and nature of all accepted presentations.
- Specific presentation date and time requests cannot be guaranteed.
- Once a specific date/time is selected, you cannot reschedule.

Email notifications will be sent to the primary author's email address by the end of February. Questions regarding the submission process should be directed to abstracts@aad.org.